Henry Wolff

Henry Ward Wolff is an Independent Director at Calithera Biosciences, Inc. He previously served as an Independent Director at MAP Pharmaceuticals LLC from 2008 to 2013, Sunesis Pharmaceuticals, Inc. from 2018 to 2021, and Portola Pharmaceuticals LLC from 2007 to 2020.
He was also an Executive Director at Russell Reynolds Associates, Inc. and Russell Reynolds Associates, Inc. (Germany) from 1985 to 1992.
Additionally, he held the position of Chief Financial Officer at Premenos Technology Corp.
from 1992 to 1998, Nuvelo, Inc. from 2006 to 2007, Abgenix, Inc. from 2004 to 2006, and DoubleTwist, Inc. from 1998 to 2002.
He was the Chief Financial Officer at QuantumShift, Inc. from 2002 to 2003.
Prior to that, he worked as a Senior Audit Manager at Pricewaterhouse LLP.
From 2007 to 2017, he served as the Chief Financial Officer & Executive Vice President at Sangamo Therapeutics, Inc. Mr. Wolff obtained his undergraduate degree from the University of California, Berkeley and holds an MBA from Harvard Business School.